Pharma Marketletter - Sanofi-Aventis’ Acomplia provides long-term cardiovascular benefits; two-year study.
Friday, December 19th, 2008New findings reported at the American Heart Association Scientific Sessions in New Orleans, Louisiana, show that first-year improvements in cardiovascular risk factors seen in obese patients treated with Sanofi-Aventis’ Acomplia (rimonabant) are sustained in the second year of therapy.
Related Re…
